189 related articles for article (PubMed ID: 35714302)
1. Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease.
Mittendorf EA; Burgers F; Haanen J; Cascone T
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35714302
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Immunotherapy: A Promising New Standard of Care.
Boydell E; Sandoval JL; Michielin O; Obeid M; Addeo A; Friedlaender A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511609
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer.
Sanber K; Rosner S; Forde PM; Marrone KA
BioDrugs; 2023 Nov; 37(6):775-791. PubMed ID: 37603233
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer.
Broderick SR
Thorac Surg Clin; 2020 May; 30(2):215-220. PubMed ID: 32327180
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer.
Conroy MR; Dennehy C; Forde PM
Lung Cancer; 2023 Sep; 183():107314. PubMed ID: 37541935
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant immune-checkpoint inhibitors in lung cancer - a primer for radiologists.
Kifjak D; Hochmair MJ; Krenbek D; Milos RI; Heidinger BH; Prayer F; Röhrich S; Watzenboeck ML; Oberndorfer F; Klikovits T; Aigner C; Sinn K; Hoda MA; Hoetzenecker K; Haug AR; Prosch H; Beer L
Eur J Radiol; 2023 Apr; 161():110732. PubMed ID: 36804313
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
8. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
[TBL] [Abstract][Full Text] [Related]
9. [Promise of Neoadjuvant Immunotherapy in Resected Non-small Cell Lung Cancer].
Yao S; Zhang Y
Zhongguo Fei Ai Za Zhi; 2020 Jan; 23(1):55-59. PubMed ID: 31948539
[TBL] [Abstract][Full Text] [Related]
10. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer].
Chen XY; Yang F
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
[TBL] [Abstract][Full Text] [Related]
12. Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence.
Vaidya P; Cohen EEW
Clin Cancer Res; 2024 Apr; 30(7):1232-1239. PubMed ID: 37955563
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant immunotherapy in nonsmall cell lung cancer.
Pall G
Curr Opin Oncol; 2021 Jan; 33(1):59-63. PubMed ID: 33229874
[TBL] [Abstract][Full Text] [Related]
14. Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy.
Gentzler RD; Riley DO; Martin LW
Curr Oncol Rep; 2020 Aug; 22(11):109. PubMed ID: 32803520
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant immunotherapy of locoregionally advanced solid tumors.
Tarhini AA; Eads JR; Moore KN; Tatard-Leitman V; Wright J; Forde PM; Ferris RL
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35973745
[TBL] [Abstract][Full Text] [Related]
16. Revisiting neoadjuvant therapy in non-small-cell lung cancer.
Saw SPL; Ong BH; Chua KLM; Takano A; Tan DSW
Lancet Oncol; 2021 Nov; 22(11):e501-e516. PubMed ID: 34735819
[TBL] [Abstract][Full Text] [Related]
17. A Pathologic Complete Response to Neoadjuvant Chemotherapy and Immunotherapy Followed by Surgery in a Patient With NSCLC.
Ma X; Li B; Li Y; Lu L; Chen H
J Thorac Oncol; 2019 May; 14(5):e104-e106. PubMed ID: 31027744
[No Abstract] [Full Text] [Related]
18. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021.
Burton EM; Amaria RN; Cascone T; Chalabi M; Gross ND; Mittendorf EA; Scolyer RA; Sharma P; Ascierto PA
J Transl Med; 2022 Jun; 20(1):271. PubMed ID: 35706041
[TBL] [Abstract][Full Text] [Related]
20. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer.
Tong BC; Gu L; Wang X; Wigle DA; Phillips JD; Harpole DH; Klapper JA; Sporn T; Ready NE; D'Amico TA
J Thorac Cardiovasc Surg; 2022 Feb; 163(2):427-436. PubMed ID: 33985811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
